Company intelligence / Profile preview

Syngulon

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Syngulon's bacteriocin-based genetic technologies have shown efficacy in laboratory settings for improving microbial fermentation efficiency and preventing contamination. The company is actively collaborating with academic partners on research programs targeting both industrial and human health applications but has not reported clinical trial results yet.

Therapeutic areas: OtherInfectious Diseases
Modalities: Genetically engineered bacteriocins (antimicrobial peptides)Genetic technologies for microbial strain engineering
Industry: Biotech

Drug pipeline

2 assets

SKINCURE

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

UCLouvainULBKU LeuvenImperial College LondonUniversity College LondonUniversidad Complutense MadridDSMCentrient PharmaceuticalsTereos

Beyond the preview

Go deeper on Syngulon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syngulon.

Explore the full profile